Daniel Prieto-Alhambra, MD PhD

Professor of Pharmaco- and Device Epidemiology at Oxford University

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Social:linkedin logotwitter logo










Prof Dani Prieto-Alhambra trained as a general practitioner in Spain (1996-2006), and then completed a European PhD in medicine and Epidemiology (2008-2011) which triggered his interest in pharmaco-epidemiology. He received formal training in Pharmacoepidemiology and Pharmacovigilance at the London School of Hygiene and Tropical Medicine, and developed an interest in rheumatology and orthopaedics completing an MSc in Musculoskeletal Sciences at University of Oxford (2012-2013). 

Dani combines his work as Professor of Pharmaco- and Device Epidemiology at the Centre for Statistics in Medicine (University of Oxford) with his role at Erasmus University Medical Center, and acts also as the Research Co-ordinator of the European Health and Evidence Network (EHDEN). He has extensive expertise in the design, curation, and analysis of electronic medical records, claims, registry and other real world data from all over the world.

Dani’s overarching professional aim is to improve patient care through the generation of reliable and relevant evidence. He sets out to do so by filling gaps in medical knowledge through the development and testing of pharmaco-epidemiological and data science methods, and the analysis of important clinical questions using observational data.

Prof Prieto-Alhambra serves as an elected member of the Steering Group of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance from December 2020 (www.encepp.eu).

Key recent publications

  • Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.
    Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Fišter K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, van der Lei J, Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostropolets A, Park RW, Prats-Uribe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto-Alhambra D; OHDSI-COVID-19 consortium.Lancet Rheumatol. 2020 Nov;2(11):e698-e711. doi: 10.1016/S2665-9913(20)30276-9. Epub 2020 Aug 21.PMID: 32864627.

  • Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study.
    Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahão MTF, Alberga A, Alghoul H, Alser O, Alshammari TM, Aragon M, Areia C, Banda JM, Cho J, Culhane AC, Davydov A, DeFalco FJ, Duarte-Salles T, DuVall S, Falconer T, Fernandez-Bertolin S, Gao W, Golozar A, Hardin J, Hripcsak G, Huser V, Jeon H, Jing Y, Jung CY, Kaas-Hansen BS, Kaduk D, Kent S, Kim Y, Kolovos S, Lane JCE, Lee H, Lynch KE, Makadia R, Matheny ME, Mehta PP, Morales DR, Natarajan K, Nyberg F, Ostropolets A, Park RW, Park J, Posada JD, Prats-Uribe A, Rao G, Reich C, Rho Y, Rijnbeek P, Schilling LM, Schuemie M, Shah NH, Shoaibi A, Song S, Spotnitz M, Suchard MA, Swerdel JN, Vizcaya D, Volpe S, Wen H, Williams AE, Yimer BB, Zhang L, Zhuk O, Prieto-Alhambra D, Ryan P.Nat Commun. 2020 Oct 6;11(1):5009. doi: 10.1038/s41467-020-18849-z.

  • Evaluation of the COVID-19 response in Spain: principles and requirements.
    García-Basteiro AL, Legido-Quigley H; 20 signatories.Lancet Public Health. 2020 Nov;5(11):e575. doi: 10.1016/S2468-2667(20)30208-5. Epub 2020 Sep 21.

  • The need for an independent evaluation of the COVID-19 response in Spain.
    García-Basteiro A, Alvarez-Dardet C, Arenas A, Bengoa R, Borrell C, Del Val M, Franco M, Gea-Sánchez M, Otero JJG, Valcárcel BGL, Hernández I, March JC, Martin-Moreno JM, Menéndez C, Minué S, Muntaner C, Porta M, Prieto-Alhambra D, Vives-Cases C, Legido-Quigley H.Lancet. 2020 Aug 22;396(10250):529-530. doi: 10.1016/S0140-6736(20)31713-X. Epub 2020 Aug 6.

  • Knee and hip replacements and the risk of revision.
    Burn E, Murray DW, Pinedo-Villanueva R, Prieto-Alhambra D. Lancet. 2019 Aug 31;394(10200):e28. doi: 10.1016/S0140-6736(19)31780-5.PMID: 31478504

  • The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study.
    Bayliss LE, Culliford D, Monk AP, Glyn-Jones S, Prieto-Alhambra D, Judge A, Cooper C, Carr AJ, Arden NK, Beard DJ, Price AJ.Lancet. 2017 Apr 8;389(10077):1424-1430. doi: 10.1016/S0140-6736(17)30059-4. Epub 2017 Feb 14.

  • Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density.
    Rodríguez AJ, Ernst MT, Nybo M, Prieto-Alhambra D, Ebeling PR, Hermann AP, Abrahamsen B.J Clin Endocrinol Metab. 2020 Oct 1;105(10):dgaa481. doi: 10.1210/clinem/dgaa481.PMID: 32717068.

  • Preschool Obesity Is Associated With an Increased Risk of Childhood Fracture: A Longitudinal Cohort Study of 466,997 Children and Up to 11 Years of Follow-up in Catalonia, Spain.
    Lane JC, Butler KL, Poveda-Marina JL, Martinez-Laguna D, Reyes C, de Bont J, Javaid MK, Logue J, Compston JE, Cooper C, Duarte-Salles T, Furniss D, Prieto-Alhambra D. J Bone Miner Res. 2020 Jun;35(6):1022-1030. doi: 10.1002/jbmr.3984. Epub 2020 Apr 7.

  • Smoking and Alcohol Intake but Not Muscle Strength in Young Men Increase Fracture Risk at Middle Age: A Cohort Study Linked to the Swedish National Patient Registry.
    Prieto-Alhambra D, Turkiewicz A, Reyes C, Timpka S, Rosengren B, Englund M.J Bone Miner Res. 2020 Mar;35(3):498-504. doi: 10.1002/jbmr.3917. Epub 2019 Dec 4.

  • Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.
    Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W, Sattar N.BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.

  • Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.
    Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R.BMJ. 2016 Jun 28;353:i3365. doi: 10.1136/bmj.i3365.

  • GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates.
    Roca-Ayats N, Balcells S, Garcia-Giralt N, Falcó-Mascaró M, Martínez-Gil N, Abril JF, Urreizti R, Dopazo J, Quesada-Gómez JM, Nogués X, Mellibovsky L, Prieto-Alhambra D, Dunford JE, Javaid MK, Russell RG, Grinberg D, Díez-Pérez A.N Engl J Med. 2017 May 4;376(18):1794-1795. doi: 10.1056/NEJMc1612804.

Key collaborators/research groups

  • The European Health Data and Evidence Network – www.ehden.eu
  • The Observational Health Data Sciences and Informatics – www.ohdsi.org
  • The Centre for Statistics in Medicine, University of Oxford – www.csm.ox.ac.uk
  • European Network of Centres for Pharmacoepidemiology and Pharmacovigilance from December 2020, European Medicines Agency - (www.encepp.eu)